Liver Tumors

  • Marcio H. Malogolowkin
  • Arthur Zimmermann
  • Jack Plaschkes
Part of the Pediatric Oncology book series (PEDIATRICO)


Hepatocellular Carcinoma Clin Oncol Liver Tumor Focal Nodular Hyperplasia Hepatocellular Carci 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bleyer A, O’Leary M, Barr R, Ries LAG (eds) (2006) Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD, p 220Google Scholar
  2. 2.
    Bosch FX, Ribes J, Borras J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19:271–285PubMedGoogle Scholar
  3. 3.
    Feraly J, Parkin DM, Pisani P (1998) GLOBOCAN Graphical Package 1: Cancer Incidence and Mortality Worldwide. IARC Press, LyonsGoogle Scholar
  4. 4.
    Chen JC, et al (1998) Hepatocellular carcinoma in children: clinical review and comparison with adult cases. J Pediatr Surg 33:1350–1354PubMedGoogle Scholar
  5. 5.
    Czauderna P (2002) Adult type vs. childhood hepatocellular carcinoma — are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol 39:19–23Google Scholar
  6. 6.
    Di Bisceglie AM, et al (1998) NIH conference. Hepatocellular carcinoma. Ann Intern Med 108:390–401Google Scholar
  7. 7.
    Chang M, et al (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855–1859PubMedGoogle Scholar
  8. 8.
    Ishak KG (1991) Hepatocellular carcinoma associated with inherited metabolic diseases. In: Tabor E, Di Bisceglie AM, Purcell RH (eds) Etiology, Pathogenesis and Treatment of Hepatocellular Carcinoma in North America. Portfolio Publishing Company, The Woodlands, Texas, pp 91–103Google Scholar
  9. 9.
    Ugarte N, Gonzalez-Crussi F (1981) Hepatoma in siblings with progressive familial cholestatic cirrhosis of childhood. Am J Clin Pathol 76:172–177PubMedGoogle Scholar
  10. 10.
    Kharsa D, et al (1990) Adenome hepatique et carcinome hepatocellulaire chez deux freres ateints de glycogenose de type I. Gastroenterol Clin Biol 14:84–89PubMedGoogle Scholar
  11. 11.
    Eriksson S, Carlson J, Velez R (1986) Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 296:1411–1412Google Scholar
  12. 12.
    Ishak KG (1979) Hepatic neoplasms associated with contraceptives and anabolic steroids. Recent Results Cancer Res 66:73–128PubMedGoogle Scholar
  13. 13.
    Sun Z, Lu P, Gail MH (1999) Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable aflatoxin metabolite M1. Hepatology 30:379–383PubMedGoogle Scholar
  14. 14.
    Christopherson WM, Mays ET (1987) Risk factors, pathology, and pathogenesis of selected benign and malignant liver neoplasm. In: Wanebo HH (ed) Hepatic and Biliary Cancer. Marcel Decker, New York, pp 17–43Google Scholar
  15. 15.
    Okuda K (2000) Hepatocellular carcinoma. Hepatology 32:225–237Google Scholar
  16. 16.
    Okuda K (2002) Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangio-carcinoma variants. J Gastroenterol Hepatol 17:401–405PubMedGoogle Scholar
  17. 17.
    Lauwers GY, et al (2002) Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 26:25–34PubMedGoogle Scholar
  18. 18.
    Edmonson H (1956) Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. Arch Dis Child 1:168–186Google Scholar
  19. 19.
    Craig JR, et al (1980) Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 46:372–379PubMedGoogle Scholar
  20. 20.
    McLarney JK, et al (1999) Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics 19:453–471PubMedGoogle Scholar
  21. 21.
    Cheuk W, Chan JK (2001) Clear cell variant of fibrolamellar carcinoma of the liver. Arch Pathol Lab Med 125:1235–1238PubMedGoogle Scholar
  22. 22.
    Berman MA, Burham JA, Sheahan DG (1988) Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and review of the literature. Hum Pathol 19:784–794PubMedGoogle Scholar
  23. 23.
    Van Eyken P, et al (1990) Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology 17:101–107PubMedGoogle Scholar
  24. 24.
    Seitz G, et al (2002) Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma. Hum Pathol 33:765–769PubMedGoogle Scholar
  25. 25.
    Paradinas FJ, et al (1982) High serum vitamin B12 binding capacity as a marker of fibrolamellar variant of hepatocellular carcinoma. Br Med J 25:840–842Google Scholar
  26. 26.
    Sheppard KJ, et al (1983) High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J 286:57Google Scholar
  27. 27.
    Wheeler K, et al (1986) Transcobalamin I as a “marker” for fibrolamellar hepatoma. Med Pediatr Oncol 114:227–229PubMedGoogle Scholar
  28. 28.
    Kane SP, et al (1978) Vitamin B12 binding protein as a tumour marker for hepatocellular carcinoma. Gut 19:1105–1109PubMedGoogle Scholar
  29. 29.
    Collier NR, et al (1984) Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet 1:538–540PubMedGoogle Scholar
  30. 30.
    Hany MA, et al (1997) A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. Med Pediatr Oncol 28:136–138PubMedGoogle Scholar
  31. 31.
    Sirivatanauksorn Y, et al (2001) Genomic homogeneity in fibrolamellar carcinomas. Gut 49:82–86PubMedGoogle Scholar
  32. 32.
    Wilkens L, et al (2000) Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. J Clin Pathol 114:867–874Google Scholar
  33. 33.
    Prokurat A, et al (2002) Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing betacatenin. Med Pediatr Oncol 39:510–518PubMedGoogle Scholar
  34. 34.
    Perilongo G, Plaschkes J, Zimmermann A (2002) Hepatic tumours. In: Souhami RL, Tannock I, Hohenberger P, Horiot JC (eds) Oxford Textbook of Oncology, Vol. 2. Oxford University Press, Oxford, pp 2657–2668Google Scholar
  35. 35.
    Rowland JM (2002) Hepatoblastoma: assessment of criteria for histologic classification. Med Pediatr Oncol 39:478–483PubMedGoogle Scholar
  36. 36.
    Buendia MA (2002) Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol 39:530–535PubMedGoogle Scholar
  37. 37.
    Zimmermann A (2002) Pediatric liver tumors and hepatic ontogenesis: common and distinctive pathways. Med Pediatr Oncol 39:492–503PubMedGoogle Scholar
  38. 38.
    Postovsky S, et al (2001) Late recurrence of combined hepatocellular carcinoma and hepatoblastoma in a child: case report and review of the literature. Eur J Pediatr Surg 11:61–65PubMedGoogle Scholar
  39. 39.
    Dumortier J, et al (1999) Recurrence of hepatocellular carcinoma as a mixed hepatoblastoma after liver transplantation. Gut 45:622–625PubMedGoogle Scholar
  40. 40.
    Chen TC, Hsieh LL, Kuo TT (1995) Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma. J Pathol 176:243–247PubMedGoogle Scholar
  41. 41.
    Kusafuka T, et al (1997) Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg 32:1175–1180PubMedGoogle Scholar
  42. 42.
    Pang A, et al (2003) Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet 146:8–15PubMedGoogle Scholar
  43. 43.
    Aoki T, et al (2004) Clinical value of alterations in p73 gene, related to p53 at 1p36, in human hepatocellular carcinoma. Int J Oncol 24:441–446PubMedGoogle Scholar
  44. 44.
    Feitelson MA, et al (2002) Genetic mechanisms of hepatocarcinogenesis. Oncogene 21:2593–2604PubMedGoogle Scholar
  45. 45.
    Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nature Genet 31:339–346PubMedGoogle Scholar
  46. 46.
    Van Tornout JM, Buckley JD, Ortega JA (1997) Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children’s Cancer Group. J Clin Oncol 15:1190–1197PubMedGoogle Scholar
  47. 47.
    Tsuchida Y, et al (1989) Three different types of alpha-fetoprotein in the diagnosis of malignant solid tumors: use of a sensitive lectin-affinity immunoelectrophoresis. J Pediatr Surg 24:350–355PubMedGoogle Scholar
  48. 48.
    Ortega JA, Siegel SE (1993) Biological markers in pediatric solid tumors. In: Pizzo AP, Poplack DG (eds) Principles and Practice of Pediatric Oncology. Lippincott, Philadelphia pp 179–194Google Scholar
  49. 49.
    Miller JH, Gates GH, Stanley P (1977) The radiologic investigation of hepatic tumors in childhood. Radiology 124:451–464PubMedGoogle Scholar
  50. 50.
    Liu P, Daneman A, Stringer DA (1985) Diagnostic imaging of liver masses in children. J Can Assoc Radiol 36:296–300PubMedGoogle Scholar
  51. 51.
    de Campo M. de Campo JF (1988) Ultrasound of primary hepatic tumours in childhood. Pediatr Radiol 19:19–24PubMedGoogle Scholar
  52. 52.
    King S, et al (1993) Value of CT in determining the resectability of hepatoblastoma before and after chemotherapy. AJR Am J Roentgenol 160:793–799PubMedGoogle Scholar
  53. 53.
    Korobkin M, et al (1981) Computed tomography of primary liver tumors in children. Radiology 139:431–438PubMedGoogle Scholar
  54. 54.
    Boechat MI, et al (1988) Primary liver tumors in children: comparison of CT and MR imaging. Radiology 169:727–732PubMedGoogle Scholar
  55. 55.
    Stocker JT, Ishak KG (1978) Undifferentiated embryonal sarcoma of the liver. Report of 31 cases. Cancer 42:336–348PubMedGoogle Scholar
  56. 56.
    Chowdhary SK, et al (2004) Undifferentiated embryonal sarcoma in children: beware of the solitary liver cyst. J Pediatr Surg 39:E9–12PubMedGoogle Scholar
  57. 57.
    Bisogno G, et al (2002) Undifferentiated embryonal sarcoma of the liver in childhood: a curable disease. Cancer 94:252–257PubMedGoogle Scholar
  58. 58.
    Uchiyama M, et al. (2001) Treatment of ruptured undifferentiated sarcoma of the liver in children. J Hepatobil Pancreat Surg 8:87–91Google Scholar
  59. 59.
    Herman P et al. (2000) Hepatic Adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg 24:372–376PubMedGoogle Scholar
  60. 60.
    Heaton ND, et al (1991) Focal nodular hyperplasia of the liver: a link with sickle cell disease. Arch Dis Child 66:1073–1074PubMedGoogle Scholar
  61. 61.
    Bouyn CL, et al (2003) Hepatic focal nodular hyperplasia in children previously treated for a solid tumour. Incidence risk factors and outcome. Cancer 97: 3103–3107Google Scholar
  62. 62.
    Reymond D, et al (1995) Focal nodular hyperplasia of the liver in children. Review of follow up and outcome. J Pediatr Surg 30:1590–1593PubMedGoogle Scholar
  63. 63.
    Reynolds M (1999) Pediatric liver tumors. Semin Surg Oncol 16:159–172PubMedGoogle Scholar
  64. 64.
    Evans AE, Land VJ, Newton WA Jr (1982) Combination chemotherapy in the treatment of children with malignant hepatoma. Cancer 50:821–826PubMedGoogle Scholar
  65. 65.
    Ortega JA, et al (1991) Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Children’s Cancer Study Group. J Clin Oncol 9:2167–2176PubMedGoogle Scholar
  66. 66.
    MacKinlay G, Pritchard J (1992) A common language for childhood liver tumours. Pediatr Surg Int 7:325–326Google Scholar
  67. 67.
    Brown J, et al (2000) Pretreatment prognostic factors for children with hepatoblastoma — results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 36:1418–1425PubMedGoogle Scholar
  68. 68.
    The Cancer of the Liver Italian Program (CLIP) Investigators (2000) CLIP, Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31:840–845Google Scholar
  69. 69.
    Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the Bclc staging classification. Semin Liver Dis 19:329–338PubMedGoogle Scholar
  70. 70.
    Leung TW, et al (2002) Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the liver Italian program staging system: a study based on 926 patients. Cancer 94:1760–1769PubMedGoogle Scholar
  71. 71.
    The Liver Cancer Study Group of Japan (1994) Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74: 2272–2280Google Scholar
  72. 72.
    Pugh RNH, et al (1973) Transection of the oesophagus for bleeding of oesophageal varices. Br J Surg 60:646–664PubMedGoogle Scholar
  73. 73.
    Tagge EP, et al (1992) Resection including transplantation for hepatoblastoma and hepatocellular carcinoma. J Pediatr Surg 21:292–297Google Scholar
  74. 74.
    Katzenstein HM, et al (2002) Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J Clin Oncol 20:2789–2797PubMedGoogle Scholar
  75. 75.
    Reyes JD, et al (2000) Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 136:795–804PubMedGoogle Scholar
  76. 76.
    Koneru B, et al (1991) Liver transplantation for hepatoblastoma. The American experience. Ann Surg 213:118–121PubMedGoogle Scholar
  77. 77.
    Otte JB, et al (2004) Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 42:74–83PubMedGoogle Scholar
  78. 78.
    Chang MH (2003) Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int 23:309–314PubMedGoogle Scholar
  79. 79.
    Bruix J, et al (2001) Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35:421–430PubMedGoogle Scholar
  80. 80.
    Sakamoto M, Hirohashi S (1998) Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection o percutaneous ethanol injection. Jpn J Clin Oncol 28:604–608PubMedGoogle Scholar
  81. 81.
    Takayama K, et al (1998) Early hepatocellular carcinomas an entity with high rate of surgical cure. Hepatology 28:1241–1246PubMedGoogle Scholar
  82. 82.
    Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 39:1434–1440Google Scholar
  83. 83.
    Mazzaferro V, et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699PubMedGoogle Scholar
  84. 84.
    Jonas S, et al (2001) Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33:1080–1086PubMedGoogle Scholar
  85. 85.
    Yao FY, et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology 33:1394–1403PubMedGoogle Scholar
  86. 86.
    Yao FY, et al (2002) Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 8:873–883PubMedGoogle Scholar
  87. 87.
    Cronin D, Millis M, Siegler M (2001) Transplantation of liver grafts from living donors into adults: too much, too soon? N Engl J Med 344:1633–1637PubMedGoogle Scholar
  88. 88.
    Sarasin F, et al (2001) Liver donor liver transplantation for early hepatocellular carcinoma: a cost-effective perspective. Hepatology 33:1073–1079PubMedGoogle Scholar
  89. 89.
    Trotter J, et al (2002) Adult-to-Adult transplantation of the right hepatic lobe from living donor. N Engl J Med 14:1074–1082Google Scholar
  90. 90.
    Lau WY, et al (2003) Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 237:171–179PubMedGoogle Scholar
  91. 91.
    Lencioni R, et al (2004) Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl 10: S91–97PubMedGoogle Scholar
  92. 92.
    Livraghi T, et al (2004) Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl 10:S98–106PubMedGoogle Scholar
  93. 93.
    Livraghi T (2003) Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. J Hepatobil Pancreat Surg 10:67–76Google Scholar
  94. 94.
    Okada S (1999) Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis 19:323–328PubMedGoogle Scholar
  95. 95.
    Buscarini L, Buscarini E, Di Stasi M (2001) Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol 11:914–921PubMedGoogle Scholar
  96. 96.
    Lencioni RA, et al (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235–240PubMedGoogle Scholar
  97. 97.
    Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442PubMedGoogle Scholar
  98. 98.
    Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261Google Scholar
  99. 99.
    Zhang Z, et al (2000) The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 89:2606–2612PubMedGoogle Scholar
  100. 100.
    Bruix J, et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578–1583PubMedGoogle Scholar
  101. 101.
    Lo CM, et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMedGoogle Scholar
  102. 102.
    Raoul JL, et al (1997) Prospective randomized trial of chemoembolization versus intra-arterial injection of 131-I labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26:1156–1161PubMedGoogle Scholar
  103. 103.
    Soini Y, et al (1996) Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 49:470–473PubMedGoogle Scholar
  104. 104.
    Huang CC, et al (1992) Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84:262–264PubMedGoogle Scholar
  105. 105.
    Chou YY, et al (1997) Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 12:569–575PubMedGoogle Scholar
  106. 106.
    Johnson PJ, et al (1978) Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1:1006–1009PubMedGoogle Scholar
  107. 107.
    Chlebowski RT, et al (1984) Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Reports 68:487–491Google Scholar
  108. 108.
    Hochster HS, et al (1985) 4’Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 3:1535–1540PubMedGoogle Scholar
  109. 109.
    Dunk AA, et al (1985) Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. J Hepatol 1:395–404PubMedGoogle Scholar
  110. 110.
    Vogel CL, et al (1977) A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 39:1923–1929PubMedGoogle Scholar
  111. 111.
    Falkson G, et al (1978) Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42:2149–2156PubMedGoogle Scholar
  112. 112.
    Tetef M, et al (1995) 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 13:460–463PubMedGoogle Scholar
  113. 113.
    Porta C, et al (1995) 5-Fluorouracil and D,L-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: a preliminary results of a phase II study. Oncology 52:487–491PubMedGoogle Scholar
  114. 114.
    Melia WM, Westaby D, Williams R (1981) Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma. Clin Oncol 7:275–280PubMedGoogle Scholar
  115. 115.
    Okada S, et al (1993) A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50:22–26PubMedGoogle Scholar
  116. 116.
    Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 51:206–210PubMedGoogle Scholar
  117. 117.
    Wierzbicki R, et al (1994) Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma. Ann Oncol 5:466–467PubMedGoogle Scholar
  118. 118.
    Lozano RD, et al (2000) Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangio-carcinoma, and gallbladder cancer). Proc Am Soc Clin Oncol 19:264a (abstract 1025)Google Scholar
  119. 119.
    Yang TS, et al (2000) Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89:750–756PubMedGoogle Scholar
  120. 120.
    Kubicka S, et al (2001) Phase II study of sytemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48:783–789PubMedGoogle Scholar
  121. 121.
    Chao Y, et al (1998) Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 78:34–39PubMedGoogle Scholar
  122. 122.
    O’Reilly EM, et al (2001) A phase II study of irinotecan in patients with advance hepatocellular carcinoma. Cancer 91:101–105PubMedGoogle Scholar
  123. 123.
    Patt YZ, et al (2003) Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21:421–427PubMedGoogle Scholar
  124. 124.
    Ji SK, et al (1996) Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma. Korean J Int Med 11:58–68Google Scholar
  125. 125.
    Falkson G, et al (1987) A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 60:2141–2145PubMedGoogle Scholar
  126. 126.
    Falkson G, et al (1984) Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 54:970–977PubMedGoogle Scholar
  127. 127.
    Al-Idrissi HY, et al (1985) Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, adriamycin and mitomycin-C Hepatogastroenterology 32:8–10PubMedGoogle Scholar
  128. 128.
    Bobbio-Pallavicini E, et al (1997) Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 33:1784–1788PubMedGoogle Scholar
  129. 129.
    Baker LH, et al (1977) Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study. Cancer Treat Reports 61:1595–1597Google Scholar
  130. 130.
    Taieb J, et al (2003) Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 98:2664–2670PubMedGoogle Scholar
  131. 131.
    Patt YZ, et al (1998) Systemic therapy with platinol, interferon alpha 2b, doxorubicin and 5-fluorouracil (PIAF) for treatment of non-resectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 17:301a (abstract 1158)Google Scholar
  132. 132.
    Leung TW, et al (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676–1681PubMedGoogle Scholar
  133. 133.
    Minischetti M, et al (2000) TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically. Br J Cancer 109:829–837Google Scholar
  134. 134.
    Lai CL, et al (1989) Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 60:928–33PubMedGoogle Scholar
  135. 135.
    Browder T, et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886PubMedGoogle Scholar
  136. 136.
    Schwartz JD, et al (2002) Thalidomide in hepatocellular carcinoma (HCC) with optional interferon-alpha upon progression. Proc Am Soc Clin Oncol 21:10bGoogle Scholar
  137. 137.
    Schwartz JD, et al (2005) Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein. Program and abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium; January 27–29, 2005; Hollywood, Florida. Abstract 134Google Scholar
  138. 138.
    Nagasue N, et al (1985) Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 89:643–647PubMedGoogle Scholar
  139. 139.
    Nagasue N, et al (1986) Estrogen receptors in hepatocellular carcinoma. Cancer 57:87–91PubMedGoogle Scholar
  140. 140.
    Chow PK, et al (2002) High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 3:1221–1226Google Scholar
  141. 141.
    Perrone F, et al (2002) Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicenter randomised controlled trial. Curr Pharm Des 8:1013–1019PubMedGoogle Scholar
  142. 142.
    Czauderna P, et al (2002) Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 20:2798–2804PubMedGoogle Scholar
  143. 143.
    Exelby PR, et al (1975) Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics surgical section survey — 1974. J Pediatr Surg 10:329–337PubMedGoogle Scholar
  144. 144.
    Haas JE, et al (1989) Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 64:1082–1095PubMedGoogle Scholar
  145. 145.
    Lack EE, Neave C, Vawter GF (1983) Hepatocellular carcinoma: review of 32 cases in childhood and adolescents. Cancer 52:1510–1515PubMedGoogle Scholar
  146. 146.
    Farhi DC, et al (1983) Hepatocellular carcinoma in young adults. Cancer 52:1516–1525PubMedGoogle Scholar
  147. 147.
    Craig J, et al (1980) Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 46:372–379PubMedGoogle Scholar
  148. 148.
    Epstein BE, et al (1999) Metastatic nonresectable fibrolamellar hepatocellular carcinoma: prognostic features and natural history. Am J Clin Pathol 22:22–28Google Scholar
  149. 149.
    Saab S, Yao F (1996) Fibrolamellar hepatocellular carcinoma: case reports and a review of the literature. Digest Dis Sic 41:1981–1985Google Scholar
  150. 150.
    Altmann HW (1990) Some histological remarks on the fibrolamellar carcinoma of the liver. Pathol Res Pract 186:63–69PubMedGoogle Scholar
  151. 151.
    Rolfes DB (1987) Fibrolamellar carcinoma of the liver. In: Okuda K, Ishak KG (eds) Neoplasms of the Liver. Springer, New York, NY, pp 137–142Google Scholar
  152. 152.
    Katzenstein HM, et al (2003) Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 97:2006–2012PubMedGoogle Scholar
  153. 153.
    Holladay ES, et al (1985) Conversion to resectability by intra-arterial infusion chemotherapy after failure of systemic chemotherapy. J Pediatr Surg 20:715–717Google Scholar
  154. 154.
    Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261Google Scholar
  155. 155.
    Rose DM, et al (1999) Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. Am J Surg 177:405–410PubMedGoogle Scholar
  156. 156.
    Malogolowkin MH, et al (2000) Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 18:1279–1284PubMedGoogle Scholar
  157. 157.
    Goiter S, et al (1987) Intraarterial chemotherapy with lipid contrast medium for hepatic malignancies in infants. Cancer 60:2886–2890Google Scholar
  158. 158.
    Ogita S, et al (1987) Intraarterial injection of anti-tumor drugs dispersed in lipid contrast medium: a choice for initially unresectable hepatoblastoma in infants. J Pediatr Surg 22:412–414PubMedGoogle Scholar
  159. 159.
    Sue K, et al (1989) Intrahepatic arterial injections of cisplatin-phosphatidylcholine-Lipiodol suspension in two unresectable hepatoblastoma cases. Med Pediatr Oncol 17:496–500PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Marcio H. Malogolowkin
    • 1
  • Arthur Zimmermann
    • 2
  • Jack Plaschkes
    • 3
  1. 1.Dept. of Hematology/OncologyKeck School Of Medicine of USCLos AngelesUSA
  2. 2.University of BernBernSwitzerland
  3. 3.Dept. of Pediatric SugeryUniversity Children’s HospitalBernSwitzerland

Personalised recommendations